BioCentury
ARTICLE | Finance

Increasing Homology

Why Deerfield wanted to increase its stake in gene therapy/editing play Homology

August 4, 2017 11:53 PM UTC

Deerfield Management decided to put more capital into Homology Medicines Inc. based on faith in the new management team’s ability to turn an AAV vector platform into gene therapy and gene editing products.

On Aug. 1, Homology raised $83.5 million in a series B round led by Deerfield. Existing investors 5AM Ventures, Arch Venture Partners and Temasek participated, as well as new investors Fidelity Management & Research Co., HBM Healthcare Investments, Maverick Ventures, Novartis AG (NYSE:NVS; SIX:NOVN), Rock Springs Capital, Vida Ventures, Vivo Capital and Alexandria Venture Investments. ...